The Goldman Sachs Group Lowers Boston Scientific (NYSE:BSX) Price Target to $93.00

Boston Scientific (NYSE:BSX) had its price objective decreased by research analysts at The Goldman Sachs Group from $98.00 to $93.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 34.02% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. Mizuho reduced their target price on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Oppenheimer lowered their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, Evercore decreased their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $106.00.

Boston Scientific Price Performance

Shares of BSX traded down $0.78 during midday trading on Friday, hitting $69.39. 5,804,928 shares of the company traded hands, compared to its average volume of 15,094,072. The stock has a 50-day moving average of $77.83 and a 200-day moving average of $91.10. Boston Scientific has a one year low of $67.56 and a one year high of $109.50. The firm has a market cap of $103.13 billion, a P/E ratio of 35.73, a PEG ratio of 1.08 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. During the same period last year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts predict that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BSX. Norges Bank bought a new stake in Boston Scientific in the fourth quarter valued at $2,199,395,000. Edgewood Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter worth about $746,655,000. Parnassus Investments LLC boosted its stake in shares of Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after purchasing an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP increased its position in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after buying an additional 3,671,548 shares during the period. Finally, Maverick Capital Ltd. purchased a new position in shares of Boston Scientific during the fourth quarter valued at about $280,735,000. 89.07% of the stock is owned by institutional investors.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Analyst/research notes show modest trims to fair value and EPS assumptions as the Street tightens growth and execution expectations; these are not sweeping downgrades but reduce upside. (Erste Group cut FY2027 EPS slightly.)
• Neutral Sentiment: Coverage/narrative piece describing analysts resetting targets and expectations for Boston Scientific, highlighting a modest downshift in fair value estimates rather than a change to the long‑term business model. Why The Narrative Around Boston Scientific (BSX) Is Shifting As Analysts Reset Expectations
• Neutral Sentiment: Sector innovation news (Stratus Medical recognized by Fortune) — relevant to the broader electrophysiology/pain therapy competitive landscape but not directly tied to BSX financials. Stratus Medical Recognized on Fortune’s America’s Most Innovative Companies List for 2026
• Negative Sentiment: Multiple securities‑class action filings and mass solicitor notices have been issued alleging that Boston Scientific misrepresented electrophysiology procedure growth; several national law firms are seeking lead plaintiffs and reminding investors of a May 4, 2026 deadline — this increases legal uncertainty and could pressure sentiment and costs. Representative notices: Gross Law Firm. BSX Shareholder Alert: Boston Scientific Corporation Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
• Negative Sentiment: Additional plaintiff solicitations and reminders from multiple firms (Faruqi & Faruqi; Rosen; Pomerantz; Portnoy; Bernstein Liebhard; Bronstein Gewirtz & Grossman; SueWallSt) amplify the litigation storyline and publicize the potential class period (generally cited as July 23, 2025–Feb 3, 2026). Example: Faruqi & Faruqi. BSX INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.